Yesterday, Dec. 16, 2015, 113 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $10.88 to $18,402,925.00.

Highlighted Stocks Traded by Insiders:

Varonis Systems (VRNS) - FREE Research Report

Evergreen Iv L.P., who is 10% Owner at Varonis Systems, sold 4,500 shares at $16.27 on Dec. 16, 2015. Following this transaction, the 10% Owner owned 3.7 million shares meaning that the stake was reduced by 0.12% with the 4,500-share transaction.

The shares most recently traded at $16.88, up $0.61, or 3.61% since the insider transaction. Historical insider transactions for Varonis Systems go as follows:

  • 4-Week # shares bought: 1,159
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 1,159
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 1,159
  • 24-Week # shares sold: 10,000

The average volume for Varonis Systems has been 149,100 shares per day over the past 30 days. Varonis Systems has a market cap of $427.6 million and is part of the technology sector and computer software & services industry. Shares are down 47.61% year-to-date as of the close of trading on Wednesday.

Varonis Systems, Inc. provides software platform for enterprises to map, analyze, manage, and migrate their unstructured data. Currently, there are 2 analysts who rate Varonis Systems a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRNS - FREE

TheStreet Quant Ratings rates Varonis Systems as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full Varonis Systems Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Basic Energy Services (BAS) - FREE Research Report

Patterson Thomas Monroe, who is President and CEO at Basic Energy Services, bought 12,000 shares at $2.37 on Dec. 16, 2015. Following this transaction, the President and CEO owned 618,501 shares meaning that the stake was boosted by 1.98% with the 12,000-share transaction.

The shares most recently traded at $2.47, up $0.10, or 4.05% since the insider transaction. Historical insider transactions for Basic Energy Services go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 1,000
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares bought: 419,100
  • 24-Week # shares sold: 1,000

The average volume for Basic Energy Services has been 3.0 million shares per day over the past 30 days. Basic Energy Services has a market cap of $102.3 million and is part of the basic materials sector and energy industry. Shares are down 65.48% year-to-date as of the close of trading on Wednesday.

Basic Energy Services, Inc. provides well site services to oil and natural gas drilling and producing companies in the United States. Currently, there are 3 analysts who rate Basic Energy Services a buy, 1 analyst rates it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BAS - FREE

TheStreet Quant Ratings rates Basic Energy Services as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, poor profit margins, weak operating cash flow and generally high debt management risk. Get the full Basic Energy Services Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

PDL BioPharma (PDLI) - FREE Research Report

Garcia Peter S, who is Vice President, CFO at PDL BioPharma, bought 15,000 shares at $3.50 on Dec. 16, 2015. Following this transaction, the Vice President, CFO owned 126,041 shares meaning that the stake was boosted by 13.51% with the 15,000-share transaction.

The shares most recently traded at $3.78, up $0.28, or 7.51% since the insider transaction. Historical insider transactions for PDL BioPharma go as follows:

  • 4-Week # shares bought: 20,000
  • 12-Week # shares bought: 20,000
  • 24-Week # shares bought: 20,000

The average volume for PDL BioPharma has been 3.9 million shares per day over the past 30 days. PDL BioPharma has a market cap of $606.9 million and is part of the health care sector and drugs industry. Shares are down 52.4% year-to-date as of the close of trading on Wednesday.

PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. The stock currently has a dividend yield of 16.17%. The company has a P/E ratio of 2.2. Currently, there are no analysts who rate PDL BioPharma a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PDLI - FREE

TheStreet Quant Ratings rates PDL BioPharma as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and a generally disappointing performance in the stock itself. Get the full PDL BioPharma Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.